Azurity & Takeda v. Cadila Healthcare: Azilsartan Patent Suit Voluntarily Dismissed
Azurity Pharmaceuticals, Takeda Pharmaceutical Company Limited, and Arbor Pharmaceuticals filed a five-patent infringement action against Cadila Healthcare and Zydus entities in the District of New Jersey over generic versions of EDARBI® and EDARBYCLOR®. The case was voluntarily dismissed without prejudice just 125 days after filing, before the defendants had answered.
Five-Patent ANDA Battle Over Azilsartan Ends Before Defendants Could Answer
On August 3, 2023, Azurity Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and Arbor Pharmaceuticals, LLC filed an infringement action in the U.S. District Court for the District of New Jersey against Cadila Healthcare, Ltd., Zydus Lifesciences Limited, and Zydus Pharmaceuticals (USA), Inc. The complaint asserted five U.S. patents — US7157584B2, US7572920B2, US9169238B2, US9066936B2, and US9387249B2 — covering azilsartan medoxomil and chlorthalidone combination products sold under the brand names EDARBI® and EDARBYCLOR®.
The recorded basis of termination is Voluntary Dismissal. The docket order states that plaintiffs, pursuant to Rule 41(a)(1)(A) of the Federal Rules of Civil Procedure, voluntarily dismissed the action without prejudice, expressly noting that defendants had not yet served an answer or dispositive motion, making such dismissal procedurally available as of right. The case closed on December 6, 2023, 125 days after filing.
The speed of dismissal — before any substantive response from defendants — and the without-prejudice posture are notable features of the public record. What specifically prompted plaintiffs to withdraw at this early juncture is not disclosed in the available record. The without-prejudice nature of the dismissal means the claims could, in principle, be refiled, but no further proceedings are reflected in the public record reviewed here.
See Complete Case & Patent Analysis →Filing to Voluntary dismissal in 125 days
Days from filing to voluntary dismissal — resolved before any defendant answer was served
US7157584B2 and four further azilsartan medoxomil patents asserted
Any generic or specialty pharmaceutical company developing azilsartan medoxomil formulations — alone or in combination with chlorthalidone or other diuretics — should treat all five asserted patents as live enforcement risks. The voluntary dismissal without prejudice creates no safe harbour: the patents remain in force and the plaintiffs retain the right to refile. ANDA filers, 505(b)(2) applicants, and contract manufacturers should all assess exposure across the full five-patent estate.
Official order — verbatim text
The dismissal was filed by plaintiffs as of right under Rule 41(a)(1)(A), requiring no judicial determination on the merits. The order confirms defendants had not yet answered, satisfying the procedural prerequisite. The without-prejudice designation means no claim or defense was adjudicated, and the public record does not disclose any terms or conditions associated with the dismissal.
Voluntarily dismissed: what the Rule 41 exit means for both parties
Rule 41(a)(1)(A): dismissal as of right before answer
Under Federal Rule of Civil Procedure 41(a)(1)(A), a plaintiff may dismiss an action without a court order by filing a notice before the opposing party serves an answer or motion for summary judgment. Because defendants had not yet answered, plaintiffs exercised this right unilaterally. The dismissal is without prejudice, meaning it does not constitute a judgment on the merits and does not bar refiling.
No court order requiredWithout prejudice: what it means and what it leaves open
A dismissal without prejudice does not extinguish the underlying claims. Plaintiffs retain the ability to refile the same infringement allegations in a future action, subject to applicable statutes of limitations and any intervening developments. Whether a refiling is contemplated or likely is not disclosed in the available public record. The distinction from a dismissal with prejudice — which would bar refiling — is legally significant for both sides.
Claims not extinguishedCadila and Zydus exit without merits ruling — but uncertainty remains
Defendants were dismissed before having to file an answer, incurring no adjudicated liability. However, because the dismissal is without prejudice, defendants cannot treat the matter as finally resolved. The five asserted patents remain in force, and the same generic products at issue — azilsartan medoxomil and chlorthalidone combinations — could be the subject of future litigation. No agreed terms are disclosed in the available record.
No merits adjudicationGeneric entry into azilsartan market remains legally unsettled
The voluntary withdrawal without prejudice leaves the patent protection landscape for EDARBI® and EDARBYCLOR® unresolved through litigation. Other generic manufacturers seeking to enter the azilsartan medoxomil market should note that all five asserted patents remain valid and enforceable on the public record. The early dismissal does not create any precedent on infringement or validity of the asserted claims.
Patents remain in forceFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Azurity Pharmaceuticals, Inc. | Company | /Search in Eureka ↗ |
| Co-Plaintiff | Takeda Pharmaceutical Company Limited | Company | Search in Eureka ↗ |
| Co-Plaintiff | Arbor Pharmaceuticals, LLC | Company | Search in Eureka ↗ |
| Defendant | Cadila Healthcare, Ltd. | Company | /Search in Eureka ↗ |
| Co-Defendant | Zydus Lifesciences Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Zydus Pharmaceuticals (USA), Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Cynthia Stencel Betz | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Mark M. Makhail | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
R&D signals in the azilsartan medoxomil and ARB combination patent space
Forward-looking patent intelligence on azilsartan formulations, Takeda and Azurity's portfolio activity, and white-space opportunities in ARB combination therapy IP.
Takeda and Azurity's azilsartan patent filing activity
The joint assertion of five patents by Takeda, Azurity, and Arbor suggests a layered, actively maintained patent estate around azilsartan medoxomil. Tracking continuation and divisional filings by these assignees can reveal whether new claims are being pursued to extend protection beyond the current patent expiry horizon — a key signal for generic timing strategies.
Layered patent estateARB + diuretic combination patent filing trends
Combination antihypertensive formulations pairing ARBs with thiazide-like diuretics such as chlorthalidone continue to attract patent activity. Monitoring filing trends in this compound class — including novel ratios, delivery mechanisms, and excipient combinations — can reveal competitive positioning and identify formulation space not yet claimed by the incumbents.
Combination therapy IPZydus and Cadila's patent and ANDA pipeline in cardiovascular drugs
Zydus Lifesciences and Cadila Healthcare maintain an active generics pipeline in cardiovascular therapeutics. Reviewing their ANDA filings and paragraph IV certifications in the ARB class, alongside their own patent filings in formulation and process IP, can indicate where they plan to compete and what defensive or design-around strategies they may be developing.
Generics pipeline watchFormulation white space near the azilsartan claim perimeter
The five asserted patents focus on specific compound forms, dosage combinations, and salt forms of azilsartan medoxomil. Adjacent claim space — including novel co-crystals, extended-release matrices, and fixed-dose combinations with agents other than chlorthalidone — may present patentable and commercially relevant white space for both innovators and specialty generics developers.
Formulation white spaceSimilar ANDA patent infringement cases in azilsartan and ARB combination drugs
Explore comparable pharmaceutical patent infringement actions in the District of New Jersey involving ARB formulations, ANDA challenges, and multi-patent assertion strategies.
What this case signals for the azilsartan and cardiology generics IP landscape
An early voluntary withdrawal over five pharma patents signals strategic recalibration — and leaves the door open for future enforcement.
Without-prejudice exits preserve optionality — monitor for refiling
When plaintiffs holding multiple patents dismiss without prejudice before any answer, it often signals strategic repositioning rather than abandonment. Competitors and generic manufacturers in the azilsartan space should monitor PACER and Orange Book listings for any refiling or related ANDA proceedings involving the same five patents and Zydus entities.
Five-patent assertion stacks signal broad claim coverage worth mapping
The simultaneous assertion of five patents across azilsartan medoxomil formulations and combination products (with chlorthalidone) suggests layered claim coverage. Any generics developer targeting EDARBI® or EDARBYCLOR® should conduct thorough FTO analysis across all five patents — US7157584B2, US7572920B2, US9169238B2, US9066936B2, and US9387249B2 — before committing to an ANDA filing.
Azurity v Cadila — key questions answered
The case was voluntarily dismissed without prejudice. Plaintiffs Azurity Pharmaceuticals, Takeda Pharmaceutical Company Limited, and Arbor Pharmaceuticals filed a notice of voluntary dismissal under Federal Rule of Civil Procedure 41(a)(1)(A) on or before December 6, 2023 — 125 days after filing. Defendants had not yet served an answer, making the dismissal available as of right. No merits determination was made.
Five U.S. patents were asserted: US7157584B2, US7572920B2, US9169238B2, US9066936B2, and US9387249B2. These patents cover azilsartan medoxomil compound, formulations, and combination products with chlorthalidone, corresponding to the branded pharmaceutical products EDARBI® and EDARBYCLOR®. All five patents remain in force; none were invalidated or adjudicated in this proceeding.
A dismissal without prejudice means no judgment on the merits was entered. Defendants are not bound by any adverse ruling, but they also received no court determination that the asserted patents are invalid or not infringed. The five patents remain enforceable, and plaintiffs retain the right to refile. The specific terms of any arrangements between the parties, if any exist, are not disclosed in the available public record.
The case record identifies Takeda Pharmaceutical Company Limited as an Other Plaintiff alongside Azurity Pharmaceuticals and Arbor Pharmaceuticals. This is consistent with Takeda's originator role in the azilsartan medoxomil compound — the active ingredient in EDARBI® and EDARBYCLOR®. The precise basis for Takeda's co-plaintiff standing (e.g. patent ownership or exclusive licensee status) is not specified in the available public record.
The products at issue were 40 mg azilsartan medoxomil and 12.5 mg chlorthalidone tablets, 40 mg azilsartan medoxomil and 25 mg chlorthalidone tablets, and 40/80 mg azilsartan medoxomil tablets — corresponding to the branded products EDARBI® and EDARBYCLOR®. The litigation is consistent with an ANDA challenge by Cadila/Zydus seeking to market generic versions of these antihypertensive drugs.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.